The UK Frontotemporal Dementia therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Frontotemporal dementia (FTD) is the name given to dementia when it is due to progressive damage to the frontal and/or temporal lobes of the brain. The right and left frontal lobes at the front of the brain are involved in mood, social behaviour, attention, judgement, planning and self-control. Damage can lead to reduced intellectual abilities and changes in personality, emotion and behaviour. The right and left temporal lobes at the two sides of the brain are involved in processing what we hear and understanding what we hear and see. Damage may lead to difficulty recognising objects or understanding or expressing language. FTD is sometimes called frontotemporal lobar degeneration. The symptoms of FTD depend on which areas of the brain are damaged. When the frontal lobes are affected first, the main changes are in personality and behaviour, and this is called behavioural-variant FTD. When the temporal lobes are affected first, there is a loss of language skills.
Frontotemporal dementia is an umbrella term used to describe a group of younger-onset neurodegenerative conditions with a typical onset between the ages of 45 and 65 years. However, dementia is not only a concern in the ageing population. Approximately, 18,000 individuals are affected under the age of 65 years. FTD affects males and females in equal proportion and can affect those as young as 30 years. The total prevalence of FTD within the younger onset dementia service is 1.33% and the prevalence within Shropshire (those within the 45–64 age group) is 0.0023%. Around 1 in 8 people who get frontotemporal dementia will have relatives who were also affected by the condition.
Market Growth Drivers
Certain factors that are driving the Frontotemporal dementia market growth include the growing prevalence of dementia and other frontotemporal disorders, increasing drug development grants and funding by the government as well as non-government organisations. The increasing prevalence of target disease and the growing geriatric population suffering from these diseases are expected to promote the growth of the market.
However, rising treatment costs and a lack of awareness among patients and physicians about Frontotemporal dementia are among the major factors acting as restraints for the Frontotemporal dementia market.